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Background: To facilitate the in vivo study of esophageal (stem) cell biology in homeostasis and cancer, novel
mouse models are necessary to elicit expression of candidate genes in a tissue-specific and inducible fashion. To
this aim, we developed and studied a mouse model to allow labeling of esophageal cells with the histone 2B-GFP
(H2B-GFP) fusion protein.
Results: First, we generated a transgenic mouse model expressing the reverse tetracycline transactivator rtTA2-M2
under control of the promoter (ED-L2) of the Epstein-Barr virus (EBV) gene encoding the latent membrane protein-1
(LMP-1). The newly generated ED-L2-rtTA2-M2 (ED-L2-rtTA) mice were then bred with the previously developed
tetO-HIST1H2BJ/GFP (tetO-H2B-GFP) model to assess inducibility and tissue-specificity. Expression of the H2B-GFP
fusion protein was observed upon doxycycline induction but was restricted to the terminally differentiated cells
above the basal cell layer. To achieve expression in the basal compartment of the esophagus, we subsequently
employed a different transgenic model expressing the reverse transactivator rtTA2S-M2 under the control of the
ubiquitous, methylation-free CpG island of the human hnRNPA2B1-CBX3 gene (hnRNP-rtTA). Upon doxycycline
administration to the compound hnRNP-rtTA/tetO-H2B-GFP mice, near-complete labeling of all esophageal cells
was achieved. Pulse-chase experiments confirmed that complete turnover of the esophageal epithelium in the
adult mouse is achieved within 7–10 days.
Conclusions: We show that the esophagus-specific promoter ED-L2 is expressed only in the differentiated cells
above the basal layer. Moreover, we confirmed that esophageal turn-over in the adult mouse does not exceed
7–10 days.
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The luminal surface of the mouse esophagus is lined by
a stratified squamous epithelium, which consists of dis-
tinct zones of cell proliferation and differentiation. Tis-
sue turnover is fueled by a population of stem cells
which are thought to reside within the basal layer adja-
cent to the basement membrane [1]. The basal cell layer
of the human esophagus is characterized by a bimodal
distribution of rarely and more frequently proliferating
cells [2]. The slow cycling cells appear to preferentially
cluster in the interpapillary zone and were proposed,* Correspondence: r.fodde@erasmusmc.nl
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reproduction in any medium, provided the orthough never formally proven, to represent stem cells
[2]. Recently, a subpopulation of mouse esophageal basal
cells has been described as having stem-like properties
such as the capacity for self-renewal and lineage-
specification [3]. These cells also have the ability to ex-
trude Hoechst dye (also referred to as ‘side population’
or SP) and are earmarked by expression of the marker
CD34 [3]. The proliferating cells within the basal cell
layer and the adjacent suprabasal layer may represent
the analogous of transit amplifying cells in the intestinal
crypt [2,4]. All basal cells can be visualized by staining
for cytokeratin 14 [3]. Thus, progenitor cells arise from
rare stem cell divisions, which then give rise to a popula-
tion of transit amplifying cells located in the basal and
suprabasal cell layers. Cell proliferation is followed byd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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zone. This zone consists of multiple layers of progres-
sively flattened and differentiated squamous cells which
function as a protective barrier [4]. Differentiated cells
above the basal layer can be visualized by cytokeratins 4
and 13 (CK4 and CK13) [3].
Because of their rapid and alarming increase during
the last 30–40 years, esophageal malignancies have be-
come the 6th leading cause of cancer death worldwide
[5]. Two major forms of esophageal cancer are known:
squamous cell carcinoma and esophageal adenocarcin-
oma (EA). EA is typically developing in patients affected
by Barrett’s esophagus, a premalignant condition charac-
terized by the progressive replacement of the normal
stratified squamous epithelium of the lower esophagus
with columnar cells of the intestinal type [6]. Barrett’s
esophagus is thought to arise as a consequence of
gastro-esophageal reflux disease and the exposure of the
esophageal epithelium to gastro-duodenal juices causing
tissue damage and inflammation. However, the molecu-
lar and cellular mechanisms underlying adenocarcinoma
and squamous cell carcinoma in the esophageal epithe-
lium are yet largely unknown. In part, this is due to the
lack of in vivo experimental tools to study the esopha-
geal stem cell niche during homeostasis and its role in
the genesis of malignancies of the squamous and adeno-
carcinoma type. Many genes have been implicated in
esophageal tumorigenesis. The temporal and spatial con-
trol over expression of specific genes can be achieved
through the use of tissue-specific and inducible trans-
genic mouse models [7]. To date, the only promoter
described in the literature to be expressed at high levels
in the esophagus is encompassed within a 0.6 kb ED-L2
fragment from the 3’ non-coding sequence of the gene
encoding the latent membrane protein-1 (LMP-1) of the
Epstein-Bar virus (EBV) [8,9]. The expression of this
promoter has been carefully characterized and is
restricted specifically to the tongue, pharynx and
esophagus [8]. Hence, we first employed the ED-L2 pro-
moter to generate a tetracycline-inducible mouse model
allowing esophagus-specific gene expression.
Results
Generation of transgenic ED-L2-rtTA mice
Transgenic ED-L2-rtTA founder lines were generated
with a construct consisting of the ED-L2 promoter
cloned in front of the reverse tetracycline transactivator
rtTA2-M2, previously described as an improved rtTA
variant (‘Tet-On’) with strongly reduced background ac-
tivity and a 10-fold increased sensitivity for doxycycline-
driven induction [10] (Figure 1A). PCR-analysis identi-
fied six founder lines 5 of which showed transmission to
the germline. Functionality of the transgene was tested by
breeding the transgenic animals with tetO-H2B-GFP miceexpressing the histone H2B-green fluorescent protein
(H2B-GFP) under the control of a tetracycline-responsive
regulatory element [11]. Compound ED-L2-rtTA/tetO-
H2B-GFP transgenic animals were administered drink-
ing water supplemented with 5% sucrose and 2 mg/ml
doxycycline (Figure 1B). Induction of H2B-GFP gene
expression was analyzed by immunohistochemistry
(Figure 1C-E) and fluorescence microscopy (Figure 2).
Three transgenic lines were identified that showed
homogeneous and high H2B-GFP expression levels
throughout the entire length of the esophagus. H2B-GFP
expression in all three independent founder lines
appeared to be restricted to the compartment of differ-
entiated cells above the basal layer though not in the
basal layer (Figure 1C-E).
Detailed analysis of ED-L2-rtTA transgene expression
To analyze in more detail, which cell layers of the
esophagus showed expression of H2B-GFP upon doxy-
cycline-induction, we performed double staining for
GFP and basal as well as non-basal cytokeratins and the
proliferation marker Ki-67. While CK14 is a marker of
all basal cells (Figure 3A), CK4 and CK13 are highly
expressed in suprabasal, spinous and granular cells
(Figure 3B-C), whereas Ki-67 expression is observed in a
subset of the basal cells (Figure 3D) [3]. Staining for
H2B-GFP and the basal markers CK14 (Figure 3A,D,G)
and Ki-67 (Figure 2C,F,I) was never observed in the
same cell. However, GFP and CK4 (Figure 2B,E,H) were
coexpressed. Thus, H2B-GFP expressing cells are located
within the differentiated cell layers above the basal cell
layer. Cells within the basal cell compartment are devoid
of H2B-GFP expression.
Compound hnRNP-rtTA mice allow complete labeling of
esophageal cells
To achieve a broader expression pattern in the various
cell layers of the esophagus, we subsequently employed
a different transgenic model expressing the reverse
transactivator rtTA2S-M2 under the control of the ubi-
quitous and methylation-free CpG island of the human
hnRNPA2B1-CBX3 gene [12]. Exclusively upon doxycyc-
line administration to the compound hnRNP-rtTA/tetO-
H2B-GFP mice, near-complete labeling of esophageal
cells was achieved (Figure 4A-B). The observation that
the vast majority of cells are labeled upon doxycycline
administration allowed us to perform pulse-chase
experiments to study the dynamics of cell turnover in
the esophagus and the alleged presence of infrequently
dividing, label-retaining cells (LRCs). To this aim, we
withdrew doxycycline from the drinking water of previ-
ously pulsed hnRNP-rtTA/tetO-H2B-GFP mice and ana-
lyzed their esophagi by GFP IHC at different time
points. As shown in Figure 4C-F and 4G, progressive
Figure 1 “Tet On” regulated expression of the H2B-GFP fusion protein in the adult mouse esophagus. A) Schematic map of the ED-L2-
rtTA fragment here developed and employed for transgenic mouse generation. B) Following doxycycline pulse, compound heterozygous ED-L2-
rtTA/tetO-H2B-GFP transgenic animals express H2B-GFP. C-E) IHC analysis of H2B-GFP expression. After 7 days of doxycycline treatment (pulse),
compound ED-L2-rtTA/tetO-H2B-GFP transgenic mice from all three founder lines (C. line 1; D. line 5, E. line 6, all 40x magnification) show strong
nuclear H2B-GFP expression.
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sal and more differentiated squamous cells persisting up
to 7 days (Figure 4D). This is in agreement with previous
studies showing a complete turnover of the human
esophageal epithelium within 4–8 days [13]. As shown
in Figure 4, upon doxycycline pulse, 83% of all cells of
the basal layer were marked with nuclear H2B-GFP. Fol-
lowing doxycycline withdrawal, LRCs were observed for
no longer than 7 days within the basal cell layer
(Figure 4G).
Discussion
This study shows that the ED-L2 promoter is not active in
the basal cell layer of the mouse esophagus where stem
cells are thought to reside. For the purpose of studying the
mechanisms of esophageal cancer onset and progression,
it is of utmost importance to drive expression of candidate
genes to distinct cell types located within the basal cell
layer. Overexpression of the human cyclin D1 oncogene
under control of the ED-L2 promoter resulted in the de-
velopment of dysplasia with late onset (16 months) [9].
Similarly, Klf5-overexpression gated by the same ED-L2
promoter results in a two-fold increase in the proliferation
of basal cells [14]. The mild hyper- and dysplasticphenotypes observed in these models suggest that ED-L2-
driven oncogene (over)expression is insufficient to pro-
mote full-blown tumor formation in the esophagus. This
is likely to be due to the non-basal expression pattern of
the viral promoter, i.e. in a compartment where progenitor
but not stem cells are thought to reside [2,4]. In the intes-
tine, loss of function mutations at the Apc tumor suppres-
sor gene have been shown to trigger tumor formation
exclusively from cycling stem cellsthough not from pro-
genitor, transient amplifying cells [15]. Likewise, it is
plausible that the same holds true for the esophagus where
oncogene expression under the non-basal ED-L2 pro-
moter is insufficient for tumor formation. The ED-L2-
rtTA mouse model is of potential use in such proof-of-
principle studies and can be employed as an example of
oncogene expression in non-basal esophageal cells. How-
ever, an esophageal promoter, which is specifically active
within the stem cell compartment, has still to be found in
future experiments.
Novel esophageal-specific promoters are needed to study
the role played by resident stem cells in homeostasis and
cancer. As shown here, a more ubiquitous promoter can be
employed to drive expression of the H2B-GFP marker pro-
tein within the esophagus. However, as described by
Figure 2 H2B-GFP expressing cells are located exclusively within the differentiated non-basal cell layers. Immunofluorescence double
staining for GFP (green, nuclear) and A,D,G) CK14 (red, basal cell layer), B,E,H) CK4 and C,F,I) CK13 (both red, non-basal cell layers) in all three
founder lines (A-C line 1; D-F line 5, G-I line 6, all 40x magnification). The dashed lines indicate the outline of the esophageal epithelium and the
border to the basal cell layer.
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throughout the body in organs such as the kidney, heart,
liver, lung and spleen [12]. So while this promoter can be
useful to study esophageal biology, it is not applicable to
specifically overexpress oncogenes within the esophagus
only. We have employed the ubiquitous promoter in a
pulse chase study and confirmed that esophageal turn-over
in the adult mouse does not exceed 7–10 days. Notably,
quiescent LRCs were detected for no longer than 7 days
within the esophageal epithelium. This observation issuggestive of the cycling nature of the resident stem cells of
the mouse esophagus. However, since complete labeling of
all esophageal basal cells after pulse was not achieved (83%,
Figure 4G), it is still feasible that the ubiquitous promoter is
specifically silenced within the quiescent, and thus poten-
tially label-retaining esophageal cells.
Conclusion
Future studies should be directed to the identification of
esophageal stem cell-specific genes and their promoters
Figure 3 IHC analysis of the squamous epithelium of the mouse esophagus. Immunohistochemistry for cytokeratin 14 marks the basal layer
(A), while cytokeratin 4 and 13 are expressed in the differentiated cell layers above the basal cells (B, C). The proliferation marker Ki-67 is
expressed in distinct basal cells (D). All images were taken at 40x magnification.
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All animal experiments were approved by the DEC
commission and performed according to institutional
and national regulations. Phenotypic analysis was
performed in both male and female animals of mixed
(C57BL6/J and CD1) genetic background. All animals
were fed ad libidum and housed in SPF facilities. The
ED-L2-rtTA2-M2 construct was generated as follows.
The rtTA2-M2 sequence, was PCR-amplified from
the pUHrT62-1 vector [10] (gift from W. Hillen,
Erlangen) using the cloning forward (5’-ATTCTC
GAGGCCGCCACCATGTCTAGACTG-3′) and the
cloning reverse (5′-TAGACGCGTTTATCCTGGGAG
CATGTCAAGG-3′) primers (Figure 1A). The PCR
product was then subcloned downstream of the ED-
L2 promoter [8] (ED-L2 vector kind gift from Joanna
B. Wilson, Glasgow) by digesting both PCR product
and vector with the restriction enzymes XhoI and
MluI, and ligating both fragments. The final vectorwas sequence verified using the sequencing pri-mers
5′-CTTTTCGGCCTGGA ACTAATC-3′ and 5′-
CTGTCCA GCATCTCGATTG-3′; (Figure 1A). The
2.1 kb expression cassette was cut out of the plasmid
backbone by BamHI and ClaI digest, gel-purified and
prepared for injection into fertilized C57BL6/J
oocytes. Founders were identified by PCR amplifica-
tion of tail DNA using transgene specific genotyping
primers (5′-CAAGACTTTCTGCGGAACAAC-3′ and
5′-GTGT CTCTCTTTCCTCTTTTG-3′, Figure 1A).
Transgenic ED-L2-rtTA animals (C57BL6/J) were bred
with tetO-H2B-GFP animals (CD1) [11] (kindly pro-
vided by E. Fuchs, New York). Transgene expression
was induced in compound heterozygous animals and
their littermates by replacing normal drinking water
with 5% sucrose water containing 2 mg/ml doxycyc-
line (Sigma, D9891, Figure 1B). Dox-treated water
was changed every 2 days. After 7 days of doxycycline
treatment, mice were sacrificed and tissues were ana-
lysed for H2B-GFP-expression. The same pulse
scheme was also applied to the compound hnRNP-
rtTA/tetO-H2B-GFP mice. After one week, pulsed
mice were withdrawn doxycycline from the drinking
water and sacrificed at 0, 5, 7 and 10 days (chase).
Figure 4 IHC analysis of H2B-GFP expression in pulse-chase experiments with compound hnRNP-rtTA/tetO-H2B-GFP mice. A) Untreated
compound animals do not express nuclear H2B-GFP. B) After 7 days of doxycycline treatment in the drinking water (pulse) the vast majority of
esophageal cells are positive for nuclear GFP expression. After the doxyxycline pulse, mice were chased (no dox in drinking water) and analyzed
at 5 (C), 7 (D), 10 (E) and 12 days (F). Images were taken at 60x magnification. (G) The average number of H2B-GFP expressing basal cells of
animals chased for 0, 5, 7, 10, 12 and 14 days is displayed. Displayed are the average percentages of H2B-GFP expressing cells from the total
population of basal esophageal cells (±standard deviation).
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Tissues were fixed in 4% PFA and embedded in paraffin.
Four μm sections were mounted on slides and stained
by HE for routine histology. Immunohistochemistry was
performed according to standard procedures using the
following antibodies: GFP (1:800, A11222, Invitrogen),
CK4 (1:100, ab11215, Abcam), CK13 (1:100, ab16112,
Abcam), CK14 (1:10000, PRB-155B, Covance) and Ki-67
(1:50, M7249, DAKO). Signal detection was performedusing Rabbit EnVision + System-HRP (K4011, Dako)
for GFP. CK4 and CK13 were detected using Goat-
anti-Mouse-HRP, CK14 using Goat-anti-Rabbit-HRP.
The average number of H2B-GFP expressing basal cells
was determined by counting ca. 300 cells in three differ-
ent sections of the esophagi of animals chased for 0, 5,
7, 10, 12 and 14 days. Displayed are the average percen-
tages of H2B-GFP expressing cells from the total popu-
lation of basal esophageal cells (±standard deviation).
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GFP (1:50, A11222, Invitrogen), Ki-67 (1:50, M7249,
Dako), CK4 (1:100, BD Pharmingen) ab11215, Abcam),
CK13 (1:100, ab16112, Abcam) and CK14 (1:1000, PRB-
155B, Covance) were employed for Immunofluorescence
analysis. Ki-67 was detected using rabbit-anti-rat-A594
(Invitrogen), CK4 and CK13 were detected using goat-
anti-mouse-A594 (Invitrogen) and goat-anti-rabbit-A488
(Invitrogen) was used for signal detection of GFP.
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